An Immunotherapy Drug, OPDIVO®, Is Found To Improve Long-Term Overall Survival for Patients with Advanced Lung Cancer
PHILADELPHIA (May 25, 2016) — In a study of those patients with advanced non-squamous non-small cell lung cancer (NSCLC), those treated with the drug OPDIVO® (nivolumab) demonstrated improved overall survival over patients treated with the drug Taxotere® (docetaxel).